[go: up one dir, main page]

MA49588A - Composition pharmaceutique pour le traitement de l'anémie dans un récipient adapté, qui conserve les ingrédients actifs séparés selon une méthode scellée :complexe ferrique avec de la caséine n-acétyl-l-aspartique et folinate pentahydrate de calcium - Google Patents

Composition pharmaceutique pour le traitement de l'anémie dans un récipient adapté, qui conserve les ingrédients actifs séparés selon une méthode scellée :complexe ferrique avec de la caséine n-acétyl-l-aspartique et folinate pentahydrate de calcium

Info

Publication number
MA49588A
MA49588A MA049588A MA49588A MA49588A MA 49588 A MA49588 A MA 49588A MA 049588 A MA049588 A MA 049588A MA 49588 A MA49588 A MA 49588A MA 49588 A MA49588 A MA 49588A
Authority
MA
Morocco
Prior art keywords
pentahciumdrate
calahciumdrate
folinate
anemia
casein
Prior art date
Application number
MA049588A
Other languages
English (en)
Other versions
MA49588B1 (fr
Inventor
Ioulia Tseti
Original Assignee
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ioulia Tseti filed Critical Ioulia Tseti
Publication of MA49588A publication Critical patent/MA49588A/fr
Publication of MA49588B1 publication Critical patent/MA49588B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49588A 2018-04-05 2019-03-22 Composition pharmaceutique pour le traitement de l'anémie dans un récipient adapté, qui conserve les ingrédients actifs séparés selon une méthode scellée :complexe ferrique avec de la caséine n-acétyl-l-aspartique et folinate pentahydrate de calcium MA49588B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20180100151A GR1009589B (el) 2018-04-05 2018-04-05 Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο

Publications (2)

Publication Number Publication Date
MA49588A true MA49588A (fr) 2020-05-20
MA49588B1 MA49588B1 (fr) 2023-08-31

Family

ID=66102020

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49588A MA49588B1 (fr) 2018-04-05 2019-03-22 Composition pharmaceutique pour le traitement de l'anémie dans un récipient adapté, qui conserve les ingrédients actifs séparés selon une méthode scellée :complexe ferrique avec de la caséine n-acétyl-l-aspartique et folinate pentahydrate de calcium

Country Status (14)

Country Link
EP (1) EP3549576B1 (fr)
DK (1) DK3549576T3 (fr)
ES (1) ES2949782T3 (fr)
FI (1) FI3549576T3 (fr)
GR (1) GR1009589B (fr)
HR (1) HRP20230688T1 (fr)
HU (1) HUE062623T2 (fr)
LT (1) LT3549576T (fr)
MA (1) MA49588B1 (fr)
PL (1) PL3549576T3 (fr)
PT (1) PT3549576T (fr)
RS (1) RS64344B1 (fr)
SI (1) SI3549576T1 (fr)
SM (1) SMT202300189T1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
IT1237509B (it) * 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
ITMO20040200A1 (it) * 2004-07-29 2004-10-29 Biofer Spa Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche.
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
EP1790356A1 (fr) * 2005-11-24 2007-05-30 Vifor (International) Ag Préparation contenant des complexes de fer(III) et des composés rédoxs
ITTO20121006A1 (it) 2012-11-20 2014-05-21 Inge Spa Dispositivo per la conservazione ermetica di una sostanza da miscelare ad un'altra contenuta in un contenitore.
ES2655238T3 (es) * 2014-12-19 2018-02-19 Ioulia Tseti Un proceso para producir complejos de caseína N-acetil-aspartilada y hierro (III) y uso de los mismos en composiciones farmacéuticas

Also Published As

Publication number Publication date
LT3549576T (lt) 2023-07-25
EP3549576B1 (fr) 2023-06-07
ES2949782T3 (es) 2023-10-03
MA49588B1 (fr) 2023-08-31
HRP20230688T1 (hr) 2023-10-13
EP3549576A1 (fr) 2019-10-09
HUE062623T2 (hu) 2023-11-28
RS64344B1 (sr) 2023-08-31
PL3549576T3 (pl) 2023-11-06
GR1009589B (el) 2019-09-11
SI3549576T1 (sl) 2023-11-30
SMT202300189T1 (it) 2023-09-06
DK3549576T3 (da) 2023-06-26
FI3549576T3 (fi) 2023-06-21
PT3549576T (pt) 2023-06-29

Similar Documents

Publication Publication Date Title
EP3345613A4 (fr) Composition pharmaceutique contenant, comme principe actif, une protéine de fusion dans laquelle un peptide pénétrant les tumeurs et un agent antiangiogenèse sont fusionnés, pour la prévention et le traitement du cancer ou de maladies associées à l'angiogenèse
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
MA43763A (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
MY192532A (en) Liquid pharmaceutical composition
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
NZ702342A (en) Pharmaceutical formulation
PH12014501985A1 (en) Il-17 antibody formulation
EP4000609A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies osseuses
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA49588A (fr) Composition pharmaceutique pour le traitement de l'anémie dans un récipient adapté, qui conserve les ingrédients actifs séparés selon une méthode scellée :complexe ferrique avec de la caséine n-acétyl-l-aspartique et folinate pentahydrate de calcium
MX2020005055A (es) Emulsiones para el tratamiento de infecciones de mucosas.
WO2018124948A8 (fr) Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α
EP3777849A4 (fr) Composition pharmaceutique, comprenant du polmacoxib et de la prégabaline, pour le traitement de la douleur
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
FR3005263B1 (fr) Composition pharmaceutique ou dietetique liquide ou semi-liquide depourvue d'amertume contenant un sel d'arginine.
EP3366292A4 (fr) Composition pour la prévention ou le traitement de l'obésité contenant de l'acide alpha-lipoïque et de la n-acétylcystéine en tant que substances actives
MA43352B1 (fr) Protéine sans phénylalanine pour le traitement de la phénylcétonurie
CN104664404A (zh) 含锌硒保健药
RU2016130965A (ru) Антисептический ветеринарный препарат
BR102015015988A8 (pt) composição líquida a base de tadalafil, para tratamento de disfunção erétil, com aplicação em sistema de spray de aerossol
EP3863643A4 (fr) Azd3355 (lesogaberan) pour le traitement et la prévention de la stéatohépatite non alcoolique (nash), de la fibrose hépatique et d'autres affections hépatiques
MA38912A1 (fr) Formulations pharmaceutiques effervescentes pauvres en sodium
MA54692A (fr) Composition pour l'agriculture anti-pathogènes liquide
EP3691665C0 (fr) Composition pharmaceutique comprenant un probiotique et un prébiotique pour prévenir l'acquisition d'infections pharmacorésistantes ou les traiter
EP3416677A4 (fr) Composition pharmaceutique comprenant hgh recombinant pour le traitement d'un déficit en hormone de croissance